日本授予实验性癌症药物专利，AIM ImmunoTech盘前股价飙升88%至1.34美元

美股速递

Mar 18

**专利获批推动股价异动** AIM ImmunoTech Inc. (AIM) 今日盘前交易中股价大幅上涨88%，报1.34美元。此次股价异动源于公司宣布其实验性癌症药物获得日本专利局授予的专利。

**药物研发背景与市场定位** 该实验性药物属于免疫疗法领域，旨在通过调节人体免疫系统对抗癌细胞。当前全球癌症免疫治疗市场持续扩张，多家生物技术公司竞相布局。日本作为全球重要的医药市场，其专利审批通常被视为药物商业化前景的重要指标。此次专利获批可能为AIM ImmunoTech未来在亚洲市场的拓展奠定基础。

**专利价值与商业化路径** 专利保护期为20年，覆盖药物成分及特定应用方法。分析师指出，专利授予不仅提升公司知识产权资产价值，还可能吸引潜在合作伙伴或收购方。不过，药物仍处于实验阶段，需完成临床试验并获监管批准方能上市。公司下一步计划包括开展更多临床研究以验证药物安全性与有效性。

**市场反应与投资者关注** 盘前交易量显著放大，显示市场对该消息反应积极。生物科技板块近期受抗癌药物研发进展推动整体活跃，多家小型生物技术公司因研发突破获市场追捧。投资者将关注公司后续临床进展及资金筹措能力，以评估长期价值。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1132176168"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132176168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132176168?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-18 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132176168","market":"us","top_or_hot":-1,"title":"日本授予实验性癌症药物专利，AIM ImmunoTech盘前股价飙升88%至1.34美元","media":"美股速递","content":"<p>**专利获批推动股价异动**\nAIM ImmunoTech Inc. (AIM) 今日盘前交易中股价大幅上涨88%，报1.34美元。此次股价异动源于公司宣布其实验性癌症药物获得日本专利局授予的专利。</p>\n<p>**药物研发背景与市场定位**\n该实验性药物属于免疫疗法领域，旨在通过调节人体免疫系统对抗癌细胞。当前全球癌症免疫治疗市场持续扩张，多家生物技术公司竞相布局。日本作为全球重要的医药市场，其专利审批通常被视为药物商业化前景的重要指标。此次专利获批可能为AIM ImmunoTech未来在亚洲市场的拓展奠定基础。</p>\n<p>**专利价值与商业化路径**\n专利保护期为20年，覆盖药物成分及特定应用方法。分析师指出，专利授予不仅提升公司知识产权资产价值，还可能吸引潜在合作伙伴或收购方。不过，药物仍处于实验阶段，需完成临床试验并获监管批准方能上市。公司下一步计划包括开展更多临床研究以验证药物安全性与有效性。</p>\n<p>**市场反应与投资者关注**\n盘前交易量显著放大，显示市场对该消息反应积极。生物科技板块近期受抗癌药物研发进展推动整体活跃，多家小型生物技术公司因研发突破获市场追捧。投资者将关注公司后续临床进展及资金筹措能力，以评估长期价值。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>日本授予实验性癌症药物专利，AIM ImmunoTech盘前股价飙升88%至1.34美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n日本授予实验性癌症药物专利，AIM ImmunoTech盘前股价飙升88%至1.34美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-03-18 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>**专利获批推动股价异动**\nAIM ImmunoTech Inc. (AIM) 今日盘前交易中股价大幅上涨88%，报1.34美元。此次股价异动源于公司宣布其实验性癌症药物获得日本专利局授予的专利。</p>\n<p>**药物研发背景与市场定位**\n该实验性药物属于免疫疗法领域，旨在通过调节人体免疫系统对抗癌细胞。当前全球癌症免疫治疗市场持续扩张，多家生物技术公司竞相布局。日本作为全球重要的医药市场，其专利审批通常被视为药物商业化前景的重要指标。此次专利获批可能为AIM ImmunoTech未来在亚洲市场的拓展奠定基础。</p>\n<p>**专利价值与商业化路径**\n专利保护期为20年，覆盖药物成分及特定应用方法。分析师指出，专利授予不仅提升公司知识产权资产价值，还可能吸引潜在合作伙伴或收购方。不过，药物仍处于实验阶段，需完成临床试验并获监管批准方能上市。公司下一步计划包括开展更多临床研究以验证药物安全性与有效性。</p>\n<p>**市场反应与投资者关注**\n盘前交易量显著放大，显示市场对该消息反应积极。生物科技板块近期受抗癌药物研发进展推动整体活跃，多家小型生物技术公司因研发突破获市场追捧。投资者将关注公司后续临床进展及资金筹措能力，以评估长期价值。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIM","symbol_name":"AIM ImmunoTech Inc.","start_time":0,"source_url":"","article_id":"1132176168","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132176168","pubTimestamp":1773839183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"AIM ImmunoTech Inc.  今日盘前交易中股价大幅上涨88%，报1.34美元。此次股价异动源于公司宣布其实验性癌症药物获得日本专利局授予的专利。该实验性药物属于免疫疗法领域，旨在通过调节人体免疫系统对抗癌细胞。当前全球癌症免疫治疗市场持续扩张，多家生物技术公司竞相布局。此次专利获批可能为AIM ImmunoTech未来在亚洲市场的拓展奠定基础。盘前交易量显著放大，显示市场对该消息反应积极。投资者将关注公司后续临床进展及资金筹措能力，以评估长期价值。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AIM":"AIM ImmunoTech Inc.","BK4557":"大麻股","BK4139":"生物科技"},"translate_title":"AIM ImmunoTech surges 88% to $1.34 premarket as Japan grants patent for experimental cancer drug","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":1},"content_text":"**专利获批推动股价异动**\nAIM ImmunoTech Inc. (AIM) 今日盘前交易中股价大幅上涨88%，报1.34美元。此次股价异动源于公司宣布其实验性癌症药物获得日本专利局授予的专利。\n**药物研发背景与市场定位**\n该实验性药物属于免疫疗法领域，旨在通过调节人体免疫系统对抗癌细胞。当前全球癌症免疫治疗市场持续扩张，多家生物技术公司竞相布局。日本作为全球重要的医药市场，其专利审批通常被视为药物商业化前景的重要指标。此次专利获批可能为AIM ImmunoTech未来在亚洲市场的拓展奠定基础。\n**专利价值与商业化路径**\n专利保护期为20年，覆盖药物成分及特定应用方法。分析师指出，专利授予不仅提升公司知识产权资产价值，还可能吸引潜在合作伙伴或收购方。不过，药物仍处于实验阶段，需完成临床试验并获监管批准方能上市。公司下一步计划包括开展更多临床研究以验证药物安全性与有效性。\n**市场反应与投资者关注**\n盘前交易量显著放大，显示市场对该消息反应积极。生物科技板块近期受抗癌药物研发进展推动整体活跃，多家小型生物技术公司因研发突破获市场追捧。投资者将关注公司后续临床进展及资金筹措能力，以评估长期价值。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}